JP2020500178A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500178A5
JP2020500178A5 JP2019523671A JP2019523671A JP2020500178A5 JP 2020500178 A5 JP2020500178 A5 JP 2020500178A5 JP 2019523671 A JP2019523671 A JP 2019523671A JP 2019523671 A JP2019523671 A JP 2019523671A JP 2020500178 A5 JP2020500178 A5 JP 2020500178A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523671A
Other languages
English (en)
Japanese (ja)
Other versions
JP7042468B2 (ja
JP2020500178A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061870 external-priority patent/WO2018093949A1/en
Publication of JP2020500178A publication Critical patent/JP2020500178A/ja
Publication of JP2020500178A5 publication Critical patent/JP2020500178A5/ja
Application granted granted Critical
Publication of JP7042468B2 publication Critical patent/JP7042468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523671A 2016-11-16 2017-11-15 Magl阻害剤 Active JP7042468B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423102P 2016-11-16 2016-11-16
US62/423,102 2016-11-16
PCT/US2017/061870 WO2018093949A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (3)

Publication Number Publication Date
JP2020500178A JP2020500178A (ja) 2020-01-09
JP2020500178A5 true JP2020500178A5 (enExample) 2020-12-24
JP7042468B2 JP7042468B2 (ja) 2022-03-28

Family

ID=62145825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523671A Active JP7042468B2 (ja) 2016-11-16 2017-11-15 Magl阻害剤

Country Status (27)

Country Link
US (2) US11059822B2 (enExample)
EP (1) EP3541820B1 (enExample)
JP (1) JP7042468B2 (enExample)
KR (1) KR20190080935A (enExample)
CN (1) CN110267962B (enExample)
AU (1) AU2017361253B2 (enExample)
BR (1) BR112019009880A2 (enExample)
CA (1) CA3043617A1 (enExample)
CL (1) CL2019001336A1 (enExample)
CO (1) CO2019004945A2 (enExample)
CR (1) CR20190239A (enExample)
DO (1) DOP2019000118A (enExample)
EA (1) EA038150B1 (enExample)
EC (1) ECSP19034535A (enExample)
ES (1) ES2952582T3 (enExample)
IL (1) IL266547B (enExample)
JO (1) JOP20190107A1 (enExample)
MA (1) MA46855A (enExample)
MX (1) MX389627B (enExample)
NI (1) NI201900049A (enExample)
PE (1) PE20191145A1 (enExample)
PH (1) PH12019501079A1 (enExample)
RU (1) RU2019115784A (enExample)
TN (1) TN2019000149A1 (enExample)
UA (1) UA125523C2 (enExample)
WO (1) WO2018093949A1 (enExample)
ZA (1) ZA201903099B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
DK3630744T3 (da) 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
JP7177825B2 (ja) 2017-08-29 2022-11-24 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
MX2021000549A (es) * 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
AU2021259496A1 (en) 2020-04-21 2022-11-10 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
IL316302A (en) 2022-05-04 2024-12-01 H Lundbeck As Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003002A (en) 1910-10-10 1911-09-12 Gustave J Martel Tire-patching device.
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
EP1948630A2 (en) * 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
WO2008023720A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2011040905A1 (en) 2009-09-29 2011-04-07 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
AU2011223898A1 (en) 2010-03-04 2012-09-13 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
MX350788B (es) * 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
JP2014005245A (ja) * 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
MX2015017961A (es) * 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
CR20160496A (es) * 2014-04-04 2017-01-02 X-Rx Inc Inhibidores espirocíclicos sustituidos de la autotaxina
US10093630B2 (en) 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
HK1249101A1 (zh) 2015-07-31 2018-10-26 辉瑞公司 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3377060B1 (en) 2015-11-20 2020-08-19 Lundbeck La Jolla Research Center, Inc. Pyrazole derivatives, processes for their preparation and uses thereof
MY194647A (en) 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
CN110709084A (zh) 2017-03-13 2020-01-17 阿比德治疗公司 双重magl和faah抑制剂
DK3630744T3 (da) 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
JP7177825B2 (ja) 2017-08-29 2022-11-24 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑

Similar Documents

Publication Publication Date Title
JP2015537008A5 (enExample)
JP2020532545A5 (enExample)
JP2019104748A5 (enExample)
RU2019116512A (ru) Ингибиторы magl
JP2019531279A5 (enExample)
JP2018529650A5 (enExample)
JP2021522280A5 (enExample)
RU2019115784A (ru) Ингибиторы magl
JP2018533593A5 (enExample)
JP2020504707A5 (enExample)
AR074165A1 (es) Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas
JP2012092103A5 (enExample)
JP2021523200A5 (enExample)
JP2020530487A5 (enExample)
JP2017522277A5 (enExample)
JP2016518434A5 (enExample)
JP2018510139A5 (enExample)
JP2017536416A5 (enExample)
JP2015504081A5 (enExample)
JP2014533695A5 (enExample)
RU2016150486A (ru) Ингибиторы бета-лактамазы
JP2016518328A5 (enExample)
RU2017107026A (ru) Ингибиторы идо
JP2016121196A5 (enExample)
JP2014511876A5 (enExample)